Stockwinners Market Radar for August 26, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:04 EDT Cathie Wood's ARK Investment bought 51.3K shares of DraftKings today

19:55 EDT Bill CEO buys $2.1M in common stock, CFO buys $1.0M in common stock - In regulatory filings, Bill disclosed that its CEO Rene Lacerte bought 42.2K shares of common stock and CFO John Rettig bought 21.1K shares of common stock on August 26th in transaction sizes of $2.1M and $1.04M. Bill shares are up 1.1% afterhours at $50.30.

19:43 EDT BHP Group says external environment in FY24 'relatively volatile' - The company stated: "BHP's external operating environment in FY24 remained relatively volatile. Our key commodity prices were mixed with significant variation in performance between individual commodities. In the near term, we expect steady global growth slightly above 3% for CY24 and CY25. Major economies are expected to diverge in their growth outlooks, with developed economies facing less of a drag from higher interest rates, China experiencing an uneven recovery among its end-use sectors, and India likely to continue as the fastest growing major economy. Geopolitical risks remain relatively elevated and are likely to remain so in the near term. Inflation has been easing across our major operating regions, although the trajectory towards central bank inflation targets will continue to be bumpy. And while wage growth has largely normalised in Chile and has recently peaked in Australia, we still expect the lagged impact from inflation and some lingering labour market tightness to impact our cost base into FY25. Demand for commodities in the developed world has been relatively soft over CY23 and into CY24 as anti-inflationary policies, sluggish industrial activity and the last of the lagged impacts of the energy crisis were felt. The impact of higher interest rates is expected to continue to restrain household consumption in the developed world for the balance of CY24, but we expect steel, copper and nickel demand to recover across the OECD. China is on track to meet official CY24 macroeconomic growth targets, but the property sector is likely to remain a drag. India is expected to continue as a bright spot for commodity demand. The Chinese economy has been volatile since CY23, with a steady recovery in a range of sectors important to copper demand, for example power infrastructure, transport and consumer durable goods. Weakness however continued in the steel-intensive real estate sector. Policymakers have acknowledged that more support is needed to embed a recovery in this sector, and in mid-CY24 a more decisive policy pivot emerged with the objective to reduce the oversupply in the market. Against this backdrop, steel production was lower in H1 CY24 compared to the previous year, however annual steel production is still expected to be more than 1 Bt for the sixth consecutive year. We believe that China's economic transition could accelerate its demand shift increasingly towards 'future-facing commodities'. The picture has been more positive in India, where a capital investment upswing continues to be well entrenched and commodity demand has been robust. The Indian economy has maintained healthy momentum after the general election, particularly in relation to demand linked to the steel sector. Over the long term, the outlook for our key commodities remains positive. We continue to expect that population growth, urbanisation, rising living standards, and the infrastructure required for decarbonisation and electrification will drive demand for steel, non-ferrous metals such as copper, and fertilisers."

18:29 EDT Smart for Life provides update on prospective acquisitions - Smart for Life provided an update on the potential expansion of the Company's acquisition pipeline and an update on its M&A activities. Currently, the company is negotiating four profitable Health & Wellness acquisitions and exploring additional prospects as part of its post-restructuring strategy. These targets include Purely Optimal Nutrition, a liquid manufacturer, an established supplement brand, and a wholesale manufacturer and distributor. Chairman A.J. Cervantes, Jr. stated, "We are on track with several potentially transformative strategic transactions. Once we finalize our upcoming 10-K and 10-Q filings, we plan to substantially accelerate our M&A activity, leveraging the potential acquisitions we've already identified. We are focused on acquiring profitable companies in the nutritional supplements and functional foods sectors. With restructuring complete, we are aggressively advancing our M&A efforts. We are targeting U.S. and foreign nutraceutical companies with $5 million to $25 million in annual revenue, prioritizing innovation, quality, and organic growth."

18:00 EDT CalciMedica director buys $201K in common stock - n a regulatory filing, CalciMedica disclosed that its director Robert Wilson bought 54K shares of common stock on August 23rd in a total transaction size of $201K.

17:53 EDT Prologis CIO Ghazal sells 5,200 common shares - In a regulatory filing, Prologis CIO Joseph Ghazal disclosed the sale of 5,200 common shares of the company on August 23 at a price of $129.07 per share.

17:15 EDT L3Harris Technologies awarded $587.39M Navy contract - L3 Technologies was awarded a $587.39M cost-plus-incentive-fee contract for the design, production and delivery of electronic warfare test articles and fleet prototypes to include 11 pod simulators, eight operational prototype pods, four jettison mass model pods, two captive mass models, two mission system prototypes, and two technique development systems as well as engineering support, integration, test and maintenance resulting in a low-band capability in support of engineering and manufacturing development of the Next Generation Jammer Low Band program for the Navy EA-18G Growler and Royal Australian Air Force. Work is expected to be completed in August 2029. This contract was competitively procured via electronic request for proposal; two offers were received. Naval Air Systems Command is the contracting activity.

17:05 EDT Luna Innovations receives noncompliance notice from Nasdaq - Luna Innovations announced that it has received a written notice from Nasdaq stating that because the company has not yet filed its Form 10-Q for the quarter ended June 30 and because the company remains delinquent in filing its Form 10-Q for the quarter ended March 31 and its Form 10-K for the year ended December 31, 2023, it is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all required periodic financial reports with the SEC. As previously announced, the company received earlier notices of non-compliance with respect to the Rule on May 17 and April 2 because it had not yet filed its Q1 2024 Form 10-Q and 2023 Form 10-K, respectively.

16:57 EDT Park Hotels & Resorts provides update on Hurricane Hone - Park Hotels & Resorts announced that its two Hawaii hotels-the 2,860-room Hilton Hawaiian Village in Honolulu and the 647-room Hilton Waikoloa Village on the Big Island-sustained no material damage from Hurricane Hone, a Category 1 hurricane that impacted the Hawaiian Islands on Sunday. Both hotels maintained power and uninterrupted services, and continue to welcome guests with all customary services and amenities available.

16:32 EDT SPI Energy discloses Nasdaq non-compliance notice - SPI Energy announced that it received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that due to the Company's failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024, with the Securities and Exchange Commission, the Company is not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1), which requires the timely filing of all required periodic reports with the SEC.

16:32 EDT Achieve Life Sciences CEO John Bencich to leave role, Richard Stewart to succeed - Achieve Life Sciences announced that Richard Stewart, Achieve's co-founder and current executive chairman, will reassume the role of CEO. John Bencich, who served as the company's CEO for the past four years, will serve as an advisor during the transition. Additionally, the company announced that Thomas King, currently the lead independent director of the board, will assume the role of executive chairman.

16:21 EDT DSS CEO Heuszel steps down, COO Jason Grady named as interim - On August 15 the Chief Executive Officer of DSS Frank D. Heuszel, announced that effective on the close of business on August 23, he will step down as the Chief Executive Officer of DSS. Mr. Heuszel's resignation as the Chief Executive Officer does not reflect any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. Effective August 23 the Board of Directors of DSS elected Mr. Jason Grady as the Company's new Interim Chief Executive Officer. Mr. Jason Grady, 50, has served as the Chief Operating Officer of DSS, Inc. since 2019, and concurrently holds the position of President at Premier Packaging Corporation since 2018, a DSS subsidiary specializing in comprehensive consumer packaging solutions.

16:16 EDT Shuttle Pharmaceuticals receives noncompliance notification from Nasdaq - Shuttle Pharmaceuticals reported that it received formal notice from Nasdaq that it is not in compliance with Nasdaq Listing Rule 5250 as a result of the company's failure to timely file its quarterly report on Form 10-Q for the period ended June 30.

16:12 EDT Sana Biotechnology appoints Dhaval Patel, M.D., CSO - Sana Biotechnology (SANA) announced the appointment of Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer. "We are thrilled to welcome Dhaval to Sana's senior leadership team and look forward to partnering with him to build the company, maximize the value of our current pipeline, and secure our long-term future," said Steve Harr, Sana's President and Chief Executive Officer. Patel was previously Executive Vice President and Chief Scientific Officer at UCB, where he played a key role in its recent pipeline transformation. He and his teams contributed to the registration of Bimzelx( Rystiggo Zilbrysq . Prior to UCB, Dr. Patel spent 10 years at Novartis (NVS), most recently as the Head of Research of the Novartis Institutes for BioMedical Research NIBR Europe. During his tenure, he led research in autoimmune

16:09 EDT Avista CEO Vermillion to retire, President and COO Rosentrater to succeed - Avista Corp Chief Executive Officer Dennis Vermillion announced to the company's board of directors that he will retire from the company in the first quarter of 2025. Vermillion will transition his duties as CEO to Avista President and COO Heather Rosentrater, who was appointed to CEO by the company's board of directors, effective January 1. As CEO, Rosentrater will retain the role of president. She has also been appointed to the board of directors, effective January 1. "Succession planning is something that we've carefully considered and purposely planned for over the years," said Vermillion. "Heather has demonstrated a strong commitment to our company, employees, communities, and shareholders. I am confident she will successfully lead Avista into the future. At every turn since joining Avista, Heather has positioned our utility to be at the forefront of innovation. She has demonstrated she possesses the values, strength, acumen, and insights to lead Avista during these unique times. I'm excited for Avista's future under Heather's leadership as CEO, the first female CEO in our company's history."

16:06 EDT Slam Corp. delisted from Nasdaq, to trade on OTC Markets - SLAM Corp. "announced that the Company, as anticipated, received a notice from The Nasdaq Stock Market LLC, stating that in accordance with Nasdaq rules, Slam's securities will be delisted from the Exchange. At the open of trading on Tuesday, August 27, 2024, Slam's securities will be suspended on Nasdaq and are expected to begin trading on the OTC Markets under the tickers "SLAM" and "SLAMW", respectively, ensuring uninterrupted market activity for its shareholders. Slam's ongoing business combination with Lynk Global, Inc., the world's leading commercially-licensed satellite-direct-to-standard-phone telecoms provider, will be materially unaffected by the transition."

16:02 EDT Criteo CEO Megan Clarken to retire within the next 12 months - Criteo announced that CEO Megan Clarken has informed the Board of Directors of her intention to retire within the next 12 months. To ensure a smooth transition, Clarken will continue to serve as CEO until her successor is named, at which time she will also step down from the Board. Clarken has also agreed to remain with Criteo in a senior advisor role providing services until any necessary transition is complete. The Board has initiated a search and engaged Heidrick & Struggles, a leading executive search firm, to assist in the process of identifying and evaluating both internal and external candidates.

15:20 EDT Lyft launches Pet Rides amid National Dog Day - In a recent blog post the company said, in part: "As part of our ongoing commitment to making rides more inclusive and tailored to our riders' needs, Lyft (LYFT) is excited to announce Pet rides, a highly requested feature from both riders and drivers. We're launching just in time for National Dog Day. This new feature allows riders to match with drivers who are comfortable having pets in their car. Riders pay a $4 fee plus tax, which they'll see included in the upfront price, and drivers will receive the full fee for every pet ride. Starting August 26, "Pet rides are available nationwide, offering a seamless and stress-free experience for pet owners. Whether you're heading to the vet, the park, or just out for a day of errands, you can now bring your beloved pet with you, knowing that they'll be paired with a driver who is ready to get them where they're going!"..Other companies in the space include Uber(UBER) and Google's (GOOG;GOOGL) Waymo. Reference Link

14:34 EDT Avangrid installed more than 488,000 solar modules at True North Solar - Avangrid recently installed the final modules at True North Solar, a significant achievement for the 238 MWac or 321 MWdc clean energy project located in Falls County, Texas. Avangrid installed more than 488,000 solar modules at the site over the past several months, accomplishing this milestone ahead of schedule. "This is a major accomplishment and we are proud of the hardworking women and men who are bringing this clean energy project onto the Texas grid," said Pedro Azagra, Avangrid CEO. "In celebrating this milestone, we look forward to finishing the project. This is yet another example of Avangrid executing on its commitment to accelerate the clean energy transition."

14:24 EDT Sunnova Energy CEO Berger sells 77,000 common shares - In a regulatory filing, Sunnova Energy chairman, president, and CEO William Berger disclosed the sale of 77,000 common shares of the company on August 23 at a price of $11.3122 per share.

13:39 EDT CRH appoints Lauren Schulz as CCO - CRH (CRH) announced the appointment of Lauren Schulz as the company's Chief Communications Officer. In this role, Lauren will lead CRH's global communications strategy, brand, and corporate narrative across all markets. Most recently, Lauren served as the Head of Global Communications at Verizon Business (VZ), where she played a key role in shaping the company's global communication initiative.

13:13 EDT Uber to launch Coco's sidewalk robots on Uber Eats - Uber and Coco announced a strategic partnership to launch Coco's sidewalk robots on Uber Eats, starting in Los Angeles this week and expanding to more cities in the months to come. "This partnership with Uber builds on Coco's existing relationships with hundreds of merchants in the Los Angeles area," Coco stated. "We're excited to welcome Coco's sidewalk robots on Uber Eats to enhance the delivery experience for both our merchants and customers. As we continue to popularize robot delivery in Los Angeles, our partnership with Coco drives us another step towards a more sustainable and autonomous future for delivery," added Noah Zych, Global Head of Autonomous Mobility & Delivery at Uber.

12:02 EDT XPeng rises 8.8% - XPeng is up 8.8%, or 61c to $7.62.

12:01 EDT Four Seasons Education rises 33.0% - Four Seasons Education is up 33.0%, or $5.28 to $21.28.

12:00 EDT Sweetgreen falls -6.2% - Sweetgreen is down -6.2%, or -$2.32 to $35.33.

11:59 EDT FTC agrees to $8.5M settlement with IAC's Care.com - The Federal Trade Commission is taking action against Care.com, alleging that the child and older adult care gig platform has "systematically deceived caregivers who were looking for jobs while failing to give families seeking care a simple way to cancel their paid memberships." In a federal court complaint, the FTC alleges that Care's marketing messages about both the number of jobs available on their site and the amount workers could expect to be paid were deceptive. Care has agreed to a settlement that will require it to turn over $8.5M to be used to refund consumers harmed by their practices, as well as requiring the company to be able to back up the earnings claims it makes and be honest about the number of jobs available on their site, the FTC announced. Reference Link

10:31 EDT Indivior announces BARDA's first order of OPVEE to combat opioids - Indivior announced the first order of OPVEE nasal spray from the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to support its ongoing national preparedness efforts and help save lives during potential synthetic opioid overdose emergencies. OPVEE is the first and only nasal rescue medicine specifically indicated for synthetic opioids like fentanyl. With its first order of OPVEE, BARDA will be able to supplement local supplies of emergency opioid overdose medications for emergency rooms, ambulances, and other sites in the United States if medical countermeasure shortages occurred during an emergency response. BARDA will use $8.7M in Project BioShield designated funding for the initial procurement. The first option was exercised under the agreement with Indivior that was announced in December 2023. BARDA has the option to purchase additional OPVEE annually under Indivior vendor managed inventory over the next nine years.

10:15 EDT Virax Biolabs Group Ltd trading resumes

10:00 EDT ESS Tech falls -6.0% - ESS Tech is down -6.0%, or -49c to $7.77.

10:00 EDT e.l.f. Beauty falls -7.7% - e.l.f. Beauty is down -7.7%, or -$13.20 to $157.75.

10:00 EDT Offerpad Solutions rises 7.8% - Offerpad Solutions is up 7.8%, or 30c to $4.16.

09:48 EDT Vipshop falls -5.4% - Vipshop is down -5.4%, or -69c to $11.99.

09:48 EDT Daqo New Energy falls -9.1% - Daqo New Energy is down -9.1%, or -$1.38 to $13.82.

09:48 EDT XPeng rises 7.0% - XPeng is up 7.0%, or 49c to $7.50.

09:41 EDT Dogness Intl Corp Class A trading resumes

09:36 EDT Dogness Intl Corp Class A trading halted, volatility trading pause

09:34 EDT Mullen Automotive enters $210M contract with Volt Mobility - Mullen Automotive announced that Volt Mobility has entered into a purchase agreement for approximately $210M to acquire 3,000 Class 1 and Class 3 EV cargo vans and trucks over a 16-month period. Mullen will receive an initial $3M deposit within 60 days and additional payments as the vehicles are delivered. The Company will begin shipping the first vehicles immediately. Mullen expects to recognize approximately $210M in revenue over the next 16 months of the agreement. Volt intends to lease these vehicles to its corporate customers based in the Middle East and Gulf States. Volt's vehicle order will be assembled at Mullen's Tunica, Mississippi-based Commercial Vehicle Facility, which is capable of producing 20,000 Class 1 and 6,000 Class 3 vehicles annually with two production shifts.

09:30 EDT ARS Pharmaceuticals announces EC approval for EURneffy - ARS Pharmaceuticals announced that the European Commission has approved EURneffy for the emergency treatment of allergic reactions on August 22, 2024. The approval of the mixed application for marketing authorization grounded on Article 8(3) of Directive 2001/83/EC by the European Commission was granted following the review of data from one of the most extensive nasal spray development programs in history involving more than 700 study participants and over 1,200 administrations, as well as studies and peer-reviewed literature substituting or supporting certain tests and studies. The pharmacodynamics and pharmacokinetics of 2 mg EURneffy were evaluated across a range of dosing conditions, including single and repeat dosing, self-administration by patients, dosing in pediatrics, and during multiple nasal conditions that can cause congestion and rhinorrhea such as nasal allergen challenge or infectious rhinitis caused by a cold/flu. EURneffy benefits from an eight-year period of data protection whereby another applicant cannot rely the data submitted as part of the EURneffy marketing authorization application, and a ten-year period of marketing protection during which a generic, hybrid or biosimilar cannot be placed on the market in the EU. The issued composition of matter and method of treatment patents covering EURneffy in Europe expire in 2039. ARS Pharma anticipates that EURneffy will be made available to patients in certain European Union Member States in Q4 2024 by a pharmaceutical company with an already established commercial footprint in Europe.

09:26 EDT Westhaven Gold provides exploration update at Shovelnose gold property - Westhaven Gold provided an exploration update at its 41,623-hectare Shovelnose gold property, situated within the prospective Spences Bridge Gold Belt, 30 kilometres south of Merritt, British Columbia. The summer/fall phase of the 2024 drill campaign has now commenced and is focused on seven new, high-priority features. 4,000 metres of diamond drilling will test targets at Line 6 North, Line 6-MIK, CSAMT-3, Romeo and three different sites at Certes. Prospecting, mapping and sampling programs conducted in 2023 and 2024, in combination with an ongoing review of geological, geochemical and geophysical data, have highlighted additional exciting prospective targets across the Shovelnose property. The majority of these targets are situated within the 'Shovelnose Corridor', a prominent trend of multielement pathfinder anomalies that extends for over 11km across the property and trends into the newly acquired claims to the southeast. High-level quartz veins and anomalous antimony-mercury values suggest that less erosion has occurred in the southeast extent of the corridor, meaning that more of the epithermal system would be preserved, raising the potential for additional discoveries. Line 6 North - testing contacts of a potential rhyolite dome and related structural elements that may be the source for broad lower grade gold mineralization intercepted in past drilling; Line 6/Mik - testing a linear 500m long gold in soil anomaly coincident with geophysically inferred structures parallel to, and ~600m southwest of, those hosting Franz-FMN-South Zone mineralization. CSAMT3 - follow-up to hole SN24-412 that intersected molybdenum rich silica healed breccias, a zone of massive to weakly banded quartz+/- calcite veinlets and a second deeper zone of trace quartz+/- calcite veinlets. The molybdenum bearing breccias suggest a late stage magmatic contribution that, in other low sulphidation epithermal systems, commonly implies proximity to high grade gold-silver mineralization. Romeo - testing a pathfinder element halo identified from geochemical sampling of exposed bedrock within an extensive mapped zone of hydrothermal brecciation supported by intersecting structures evident in the detailed geophysical coverage. Certes Trend -Certes is a 3km long concentration of strongly anomalous pathfinder elements in rock and soil samples situated some 8km east-southeast of the Franz-FMN-South Zone along the same geophysical/geochemical corridor. Extent of the Certes Trend is limited by the previous property boundary. Westhaven has acquired additional claims to the east and will be conducting prospecting and sampling work on that new ground this season. Banded and laminated mercury-bearing chalcedony cobbles and boulders found at surface amongst andesite subcrop at the northwestern end of the current Certes Trend are indicative of near surface low sulphidation epithermal deposits, suggesting preservation of an entire system in the Certes area beneath an andesite cap. Drilling to identify and evaluate potential controlling structures will test three areas along the Certes Trend, each spaced about 1km apart. Certes 1 - testing the northwestern end near the most extensive banded quartz occurrences, where bedrock pathfinder geochemical anomalies are dominated by a mercury signature and a detailed ground magnetic survey was recently completed Certes 2 - testing the central part of the Certes Trend where antimony becomes the dominant pathfinder, and prominent cross structures interrupt the aeromagnetic data Certes 3 - testing the southeastern part of the currently recognized known trend where both mercury and antimony anomalies are supported by other pathfinder elements and favourable surface geology Westhaven is reporting assays for 10 holes as part of the ongoing, multi-phase drill campaign at the Shovelnose gold property. The spring phase of the drill program was announced in late March and completed in late June. Utilizing the information generated from this drilling, in conjunction with the ongoing exploration work, the summer/fall phase of the 2024 drilling campaign has commenced. Given the property location and access, Westhaven can drill year-round at the Shovelnose.

09:17 EDT Exicure announces 1-for-5 reverse stock split - Exicure announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock. The company expects that the reverse stock split will become effective at 5:00 pm on Tuesday, August 27 and its common stock will begin trading on a split-adjusted basis at the open of trading on Wednesday, August 28 under the new CUSIP number 30205M 309. Exicure's common stock will continue to trade on the Nasdaq Capital Market under the symbol (XCUR). The reverse stock split is an effort to regain compliance with Nasdaq's listing rules. The reverse stock split was approved by the company's stockholders at its special meeting of stockholders held on August 20 to be effected by the company's board of directors within approved parameters. The company's board of directors approved the reverse stock split at a ratio of 1-for-5 on August 20.

09:11 EDT Sacks Parente Golf says Handy resigned as Chief Financial Officer - In a regulatory filing, Sacks Parente Golf (SPGC) disclosed that effective August 23, Steve Handy resigned as the Chief Financial Officer of the company to take the position of Chief Financial Officer of RDE, Inc. (RSTN). "The company is actively looking for a replacement for Mr. Handy, and is currently interviewing candidates. Mr. Handy's resignation was not the result of any disagreement with the company," Sacks Parente stated. Reference Link

09:09 EDT Zoom Video appoints Fenger to board of directors - Zoom Video Communications (ZM) announced that it has appointed Mike Fenger, vice president, VP, Worldwide Sales, Apple (AAPL), as an independent director on Zoom's Board of Directors effective immediately.

09:07 EDT Capital Clean Energy Carriers completes corporate conversion, name change - Capital Clean Energy Carriers Corp. announced completion of the conversion from a Marshall Islands limited partnership named "Capital Product Partners L.P." to a Marshall Islands corporation and adoption of a new corporate identity with a change in name to "Capital Clean Energy Carriers Corp." and Nasdaq stock market ticker to "CCEC". The company said, "The Conversion and the Name Change are key milestones in our strategic pivot towards the transportation of various forms of natural gas to industrial customers, including liquefied natural gas and new commodities emerging as a result of the energy transition, as initially announced in November 2023. To achieve our strategic pivot, we agreed in November 2023 to acquire 11 newbuild LNG/C vessels, of which five vessels are already on the water and the remaining six vessels are expected to be delivered between the first quarter of 2026 and the first quarter of 2027. In June 2024, we also ordered 10 state-of-the-art, high-specification gas carriers, including four unique handy multi gas carriers that can carry liquid CO2. These, along with the Newbuild LNG/C Vessels, collectively form the "Energy Transition Vessels". This $3.9 billion investment, notable both in asset value and scope, demonstrates our commitment to becoming a leading provider of transportation for LNG and other clean fuels. We have already made significant progress on our refocus of the business with 12 latest generation LNG/C vessels currently on the water plus the disposal of seven legacy container vessels during the first half of 2024. Upon delivery of our remaining Energy Transition Vessels between the first quarter of 2026 and the third quarter of 2027, we expect to become the largest U.S.-listed LNG shipping company and will offer our industrial customers a full range of transportation solutions."

09:06 EDT Brilliant Earth promotes Catlett to CBO, Dziesietnik to COO - Brilliant Earth Group announced the promotions of two key members of its executive team, Pamela Catlett to Chief Brand Officer, CBO, and Sharon Dziesietnik to Chief Operations Officer, COO. These appointments underscore the Company's focus on continuing to drive long-term growth and build operational excellence.

09:03 EDT noco-noco announces grant of temporary exception to remain listed on Nasdaq - noco-noco received a hearing decision letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC. The Decision Letter gave the Company an exception period until October 30, 2024 to regain compliance with Listing Rule 5550(a) and Listing Rule 5550(b) or any of the alternatives outlined in Listing Rule 5550(b). Accordingly, the Nasdaq Hearings Panel granted the Company's request for continued listing on The Nasdaq Capital Market, subject to certain conditions, including the reverse stock split, a series of debt and equity financings, and prompt notification of any significant events during the exception period that may affect the Company's compliance with Nasdaq requirements.

09:02 EDT Professional Diversity Network rebrands job board operations as TalentAlly - Professional Diversity Network announced the rebranding of its job board operations to TalentAlly. TalentAlly LLC will now operate as a standalone subsidiary of Professional Diversity Network, Inc. Despite challenges in the recruitment market, PDN's job board service revenue increased by 3.2% in the first half of this year compared to last year. Consequently, the Company has decided to intensify its focus on its job board recruitment business, intending to significantly advance its commitment to diversity recruitment and inclusive hiring practices. The company said, "This strategic rebranding enables the company to connect with, market to, and expand its network of job seekers from diverse backgrounds. TalentAlly will continue to empower individuals to grow their careers with the support of its diverse network of partners and inclusive employers, career fairs, networking opportunities, mentorship programs, and more. Furthermore, with the launch of TalentAlly, the company will focus on career development and strategic recruitment by offering a continually updated library of resources for job seekers and recruiters. As job seeker quantity and quality increase, the company anticipates an increase in employers' recruiting from its network."

08:59 EDT Bloomin' Brands appoints Michael Spanos as CEO - Bloomin' Brands (BLMN) announced that Michael Spanos has been appointed CEO of the company. Spanos will begin his new role in Tampa on September 3. Former CEO David Deno announced on May 7, his planned retirement as CEO and from the board of directors. Spanos joins the company from Delta Air Lines (DAL) where he served as executive VP and COO.

08:54 EDT 5E executes debt commitment letter to issue $6M of convertible notes - The Company announced it has entered into debt commitment letters whereby it will issue an aggregate of $6.0 million in senior secured convertible notes to Ascend Global Investment Fund SPC and Bluescape Energy Partners at a conversion price reflecting a premium of 25% to the registered direct offering price. The Notes will mature in August 2028 and pay interest in-kind semi-annually at a rate of 10%, and the closing of the Notes is expected to occur in September 2024. Additional details regarding the Notes and the debt commitment letters are included in a current report on Form 8-K filed by the Company. The Notes will be sold in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933.

08:52 EDT Quest Diagnostics completes acquisition of LifeLabs - Quest has acquired 100% of the equity of LifeLabs. The transaction meets all of Quest's criteria on growth, profitability and returns. Quest expects the transaction to generate approximately $710M in annual revenues. The company expects the transaction to be slightly dilutive to GAAP earnings per share, due primarily to amortization of intangibles and other items, but 10c-15c accretive to adjusted EPS, in the first 12 months after closing. The company will provide updated financial guidance for the full year 2024 on its third quarter 2024 earnings call in October 2024. Additional terms were not disclosed.

08:50 EDT Wearable Devices announces enhanced gesture technology for Mudra Band - Wearable Devices announces the latest upgrade to the Mudra Band - enhanced gesture control functionality for the Apple Watch. This new feature enhances convenience by enabling quick, hands-free control for common tasks, and significantly improves accessibility for older Apple Watch models which do not support some of the Apple Watch double tap gesture.

08:39 EDT Ainos CEO 'profoundly optimistic' about what the future holds - Ainos provided an update letter to shareholders from its Chairman, President, and CEO Chun-Hsien Tsai, which read in part, "We embark our smell digitalization journey from the healthcare market. Looking ahead into the near future, we believe the underlying mega-trend is that as population ages, increasing demand for healthcare will collide with a labor shortage, potentially compromising the quality of health tests. We believe telehealth-friendly point-of-care tests will be crucial in reducing the burden on healthcare workers. We anticipate that VOC could be powerful biomarkers for detecting diseases and enabling easy, efficient health monitoring. Powered by AI Nose, we are making POCTs more consumer-friendly, telehealth-compatible, AI-driven, and poised to benefit more people. AI Nose will become increasingly accurate as we train the platform with more data...As we reflect on our achievements and strategic moves, we remain profoundly optimistic about what the future holds. The milestones we've reached and the strategic programs we are advancing reinforce our confidence in the transformative potential of AI Nose technology. We are poised to leverage our VOC technological advancements or strategic partnerships to drive significant impact across multiple aspects, from enhancing POCTs for better women's health to revolutionizing elderly care as well as expansion into smart manufacturing. We believe that the progress we have made positions us well for continued growth and success. As we move forward, we remain focused on executing our plans with precision and agility, continuously pushing the boundaries of innovation. We are excited about the opportunities ahead and we have confidence in our strategic initiatives for empowering our mission of digitizing smell across diverse scenarios. Thank you for your continued support in our journey."

08:36 EDT Sonoma, MicroSafe announce Australian TGA approval for NanoCyn extended claims - Sonoma Pharmaceuticals and its partner, the MicroSafe Group DMCC, announce that the Australian Therapeutic Goods Administration has approved extended claims for Nanocyn Disinfectant and Sanitizer, which is manufactured by Sonoma for its partner MicroSafe using Sonoma's patented Microcyn technology. Nanocyn was previously approved by the TGA and entered into The Australian Register of Therapeutic Goods with a 15 second kill time against SARS-CoV-2, and a 30 second kill time against Norovirus, Influenza A, and bacteria, such as Staphylococcus aureus, E. coli, Pseudomonas aeruginosa. The TGA has now also approved Nanocyn for use against Candida auris and Clostritium Difficile in ten minutes.

08:35 EDT Comscore, FreeWheel announe partnership to enhance privacy-resilient CTV - Proximic by Comscore and FreeWheel announced a partnership to support privacy-resilient ID-free audiences for CTV. The innovation will provide publishers with streamlined access to future-proofed audience monetization tools and provide buyers the ability to reach targeted audiences at scale across premium CTV content.

08:34 EDT RDE appoints Steve Handy as Chief Financial Officer - RDE (RSTN) announces the appointment of Steve Handy as its Chief Financial Officer. He joins RDE from Sacks Parente Golf, Inc. (SPGC), where he was Chief Financial Officer in its Initial Public Offering.

08:32 EDT Lixte Biotechnology announces first patient dosed in trial with NKI - LIXTE Biotechnology announced the dosing of the first patient in a new clinical trial in collaboration with the Netherlands Cancer Institute, NKI, and supported by F. Hoffmann-La Roche for treatment of unresponsive metastatic colorectal cancer. As part of the clinical trial, LIXTE is providing its lead compound, LB-100, and Roche is providing atezolizumab through the imCORE Network, a global academic-industry partnership that aims to accelerate cancer immunotherapy research through institution-sponsored studies.

08:30 EDT Sealsq utilizes Swiss data centers to store, process data from sensors, semis - SEALSQ Corp is utilizing ultra-secure data centers in Switzerland to store and process vast amounts of data generated by its sensors and semiconductors. As IoT devices continue to collect critical information across various sectors-ranging from smart cities and consumer devices to industrial automation and smart grids-there is an increasing need for robust infrastructure capable of managing the massive datasets these devices produce. The IoT data landscape is characterized by its high volume, diverse structure, and real-time requirements. Data streams include everything from telemetry and video feeds to unstructured machine logs and environmental metrics, all of which must be processed with ultra-low latency to derive actionable insights. Switzerland's strategic push toward digital sovereignty aligns perfectly with SEALSQ's objective. The country is in the process of developing an independent digital infrastructure, the Swiss Government Cloud, slated to be operational by 2026. This investment, costing CHF 319.4 million, will not only support federal agencies but also provide a secure environment for cantons, cities, and local municipalities. Switzerland's emphasis on digital sovereignty transcends mere data protection-it focuses on harnessing data-driven innovation while maintaining control over essential digital resources. SEALSQ's adoption of this infrastructure reflects a commitment to both security and technological independence.

08:15 EDT PetroChina says global economy expected to maintain moderate growth in 2H24 - The company said, "In the second half of 2024, the global economy is expected to maintain moderate growth and the Chinese economy will remain on an upward trend. The Company will continue to promote high-quality development and adhere to the five major development strategies: innovation, resources, market, internationalization and green and low-carbon development. It will actively respond to market changes, adjust and optimize production and operation strategies on a timely basis, and maintain safe, stable, and profitable operations across oil and gas value chains and of other businesses. The Company will further enhance its development quality and profitability, striving to create greater value for its shareholders."

08:12 EDT MoneyLion announces $20M stock repurchase authorization - MoneyLion I announced that its Board of Directors has authorized the repurchase of up to $20M of MoneyLion's outstanding Class A common stock .

08:10 EDT CarnoSyn Brands showcases TriBsyn at 46th ESPEN Congresss - Natural Alternatives International and CarnoSyn Brands will exhibit at the 46th ESPEN Congress on Clinical Nutrition & Metabolism in Milan, Italy on September 7-10, 2024. ESPEN 2024 offers a unique platform for companies to present and educate on innovative science in clinical nutrition and metabolism, fostering collaboration with physicians, dietitians, pharmacists, nutritionists, scientists, and nurses. The NAI and CarnoSyn Brands team will be available at stand #16 to discuss the latest clinical evidence of TriBsyn, a patent-pending formula that utilizes proprietary technology to increase beta-alanine bioavailability and absorption, while effectively eliminating the common paresthesia sensation associated with efficacious dosages of beta-alanine. TriBsyn provides new opportunity to reach untapped consumers from older adults to vegans and anyone focused on wellness. Congress attendees are invited to visit the stand to learn more about this new product innovation.

08:09 EDT Johnson & Johnson CHRO Peter Fasolo to retire, Kristen Mulholland to succeed - Johnson & Johnson announced that Peter Fasolo will retire from his position as executive VP, chief human resources officer at the end of this year, following 16 years of leadership and service to the company. He will be succeeded in this role by Kristen Mulholland. Mulholland will also be appointed as a member of Johnson & Johnson's executive committee, effective October 1. Fasolo and Mulholland will work together during a transition period until Fasolo's retirement at the end of this year.

08:09 EDT Quantum implements1-for-20 reverse stock split - Quantum Corporation announced it will implement a 1-for-20 reverse stock split of its issued and outstanding shares of common stock. The reverse stock split is intended to increase the per share trading price of its common stock to satisfy the continued listing standards of The Nasdaq Stock Market . The reverse stock split will not affect any stockholder's percentage ownership interest in the Company. At the effective time, every 20 issued shares of common stock will be converted into one share of common stock. To the extent the reverse stock results in any of the Company's stockholders being entitled to a fractional share, any such fractional share will be rounded up to the nearest whole share. The reverse stock split will reduce the number of outstanding shares of the Company's common stock from approximately 95,849,938 shares to approximately 4,792,497 shares. Proportionate adjustments will be made to the number of shares of common stock underlying the Company's outstanding equity awards, warrants, and the maximum number of shares issuable under its equity incentive plans, as well as the exercise or conversion price, as applicable. The reverse stock split will not affect the par value of the Common Stock.

08:08 EDT G2 Goldfields reports 2024 results, files revised NI 43-101 technical report - G2 Goldfields reported its financial results for the fourth quarter and year ended May 31, 2024. Dan Noone, President and CEO, commented: "2024 was a milestone year for the Company. We raised approximately $22 million in January from AngloGold Ashanti, which was subsequently augmented by the $42 million private placement completed in August. This strong cash position will allow us to continue to advance our high grade OKO project and execute our exploration plans for our district scale land package." G2 also filed a revised independent technical report on SEDAR+, which supersedes and replaces the technical report the Company filed on May 17, 2024. The Revised Technical Report is still entitled "NI 43-101 Technical Report and Mineral Resource Estimate for the Oko Gold Property in the Co-operative Republic of Guyana, South America," with the same effective date of March 27, 2024. The date of the Revised Technical Report is June 20, 2024, and there was no change to the mineral resource estimate announced by the Company in a news release dated April 3, 2024. The Revised Technical Report was prepared to replace Figures 1.4, 14.14 and 25.4, which show the grade-tonnage curve for the Ghanie zone underground, because they inadvertently replicated the data for the open pit.

08:07 EDT Alzamend Neuro executed deal to provide sufficient capital for 18 months - " We raised capital through an at-the-market sales agreement in the fourth quarter of 2023 through the first quarter of 2024, which we strategically utilized from time to time with a goal of not disrupting the market. We also entered into two separate securities purchase agreements in 2024. The first one with an entity associated with our founder and largest stockholder, pursuant to which we have received $2.1M in gross proceeds to date, and which the investor has the right to purchase up to an additional $3.9M of securities through March 31, 2025. The second agreement with an outside investor, pursuant to which we have received $7M in gross proceeds to date. Under the second agreement, the investor is obligated to purchase, subject to certain conditions, up to an additional $18M of securities through January 2026. Please see our Securities and Exchange Commission filings for additional information regarding the securities purchase agreements described above and the terms of such financing transactions," said the company's management.

08:06 EDT Assure Holdings announces further extension of exchange offer - Assure Holdings has extended the expiration date of its exchange offer relating to the Company's 9% Convertible Debentures due 2023 and 2024. As a result of the extension, the Exchange Offer is now scheduled to expire at 11:59 p.m., on September 6, 2024 unless further extended. The Offer was originally scheduled to expire at 11:59 p.m. on July 19, 2024, and has been extended several times to now expire at 11:59 p.m., on September 6, 2024. Except for the extension of the Expiration Date, all of the other terms of the Offer remain as set forth in the Offer Letter dated June 21, 2024, as amended, and a Schedule TO related thereto, as filed with the U.S. Securities and Exchange Commission on June 21, 2024, as amended. As of 11:59 p.m. on August 23, 2024, approximately $2.0 million in principal face amount of Assure Convertible Debentures have been tendered into the Offer.

08:05 EDT Meridianbet shortlisted for sports betting, iGaming license in Brazil - Golden Matrix Group announced that its subsidiary, Meridianbet, has been shortlisted for an exclusive sports betting and iGaming license in Brazil. The application, filed under request number 56.195.600/0001-07, positions Meridianbet among a select group of global operators who will be part of one of the most anticipated market launches in the global sports betting and iGaming industry. The window for prioritized license applications in Brazil closed on August 20, 2024, with a total of 113 operators submitting their applications ahead of the deadline. By securing its place in this priority group, Meridianbet has ensured that its license will be processed by January 1, 2025, which is the forecasted launch date for Brazil's legal sports betting and iGaming market.

08:03 EDT McKesson to acquire controlling interest in Core Ventures for $2.49B in cash - McKesson announced that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, or Core Ventures. Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, a physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures. McKesson will purchase its controlling interest for approximately $2.49B in cash, which will represent approximately 70% ownership. Following completion of the transaction, Core Ventures will be part of the Oncology platform, and financial results will be reported within McKesson's US Pharmaceutical segment. The transaction is subject to customary closing conditions, including necessary regulatory clearances. Following the close of the transaction, FCS, a practice with more than 250 physicians and 280 advanced practice providers, across nearly 100 locations in Florida, will remain independently owned and FCS will join McKesson's The US Oncology Network.

08:02 EDT Intelligent Living Application Group, Specifix enter cooperation agreement - Intelligent Living Application Group announced that, on August 26, the company entered into a strategic cooperation agreement with Specifix Limited, one of the leading companies in artificial intelligence assisted robotics research and development in Hong Kong.

07:57 EDT Columbia Financial receives regulatory approval for Freehold Bank merger - Columbia Financial announced that Columbia Bank has received the requisite regulatory approval from the Office of the Comptroller of the Currency necessary to merge Freehold Bank with and into Columbia Bank. The transaction is expected to be completed on October 5, 2024, which is also the anticipated systems conversion date for the merger. The closing of the merger is subject to customary closing conditions.

07:42 EDT NanoViricides investigating MEURI protocol for using NV-387 to treat MPOX - NanoViricides reports that it is investigating the possibility of using NV-387 for the treatment of MPOX patients under the WHO MEURI protocol, in light of the recent WHO PHEIC declaration for the current 2024 MPOX outbreak that is rapidly spreading into more than ten countries in Africa with additional cases detected in Thailand and Sweden. MEURI, i.e. Monitored Emergency Use of Unregistered and Investigational Interventions, is an ethical protocol developed by the World Health Organization to evaluate the potential use of experimental drugs in the event of public health emergencies. The Company believes that the MEURI protocol may be applicable for the evaluation of NV-387 for the treatment of MPOX infection in patients. NV-387 has completed Phase I clinical trial for safety and tolerability studies in healthy subjects with no adverse events reported indicating excellent safety and tolerability. NV-387 has demonstrated strong improvement in survival in animal model studies matching that of the currently approved drug, tecovirimat, indicating excellent effectiveness. MPOX Clade 1/1b require development of new therapeutics due to limitations of existing therapies. Additionally, the Company has also found that NV-387 was superior to or equivalent to existing drugs in non-clinical animal trials in the case of three major classes of respiratory viruses: RSV, Influenza, and COVID; the so-called "triple-demic" respiratory viruses. The Company believes that NV-387, as a single broad-spectrum antiviral drug that can treat a large number of viruses, could be as revolutionary for the treatment of viral infections as penicillin was to bacterial infections, when its effectiveness is proven in human clinical trials. NV-387, the Company's novel broad-spectrum antiviral treatment was found in an animal model study emulating the direct skin infection by the virus to be as effective as the current approved drug tecovirimat. Direct skin infection is thought to be the major mode of transmission of the MPOX virus in the current epidemic of MPOX Clade 1 and Clade 1b, just as it was found to be the main mode of transmission in the 2022 MPOX epidemic of Clade 2. In this lethal animal model virus infection study, oral treatment with NV-387 led to the same extent of increase in survival as oral treatment with tecovirimat. Additionally, treatment with the Company's formulation containing both NV-387 and tecovirimat, called NV-387-m-T, led to a much greater improvement in survival than either NV-387 or tecovirimat. Increase in survival is a quantitative indicator of effectiveness of the treatment in this model. In this study, mice were lethally infected with the ectromelia virus, intradigitally by scoring skin on footpads. This model emulates direct infection of the virus by skin abrasion. It is believed that direct skin-to-skin contact is the dominant mode of transmission of MPOX in the current 2024 MPOX Clade 1/1b global public health emergency, as it was in the 2022 MPOX Clade 2 epidemic. Mice in different groups were were treated orally with tecovirimat, NV-387, or NV-387-m-T, or vehicle. Ectromelia virus is in the same class as smallpox and mpox viruses, and has been used as a validated model for orthopoxvirus drug development. NV-387 acts by a novel mechanism that the Company calls "Re-Infection Inhibition", meaning the drug blocks the virus from being able to infect cells in the first place, a mechanism which is distinctly different from that of neutralizing antibodies or entry inhibitors. Tecovirimat, on the other hand, inhibits the release of the virus particles after they have already made thousands of copies in a cell. These mechanisms are complimentary to each other, leading to enhanced effect when both drugs are used simultaneously. The Company developed a special oral formulation for being able to deliver both drugs simultaneously, called NV-387-m-T.

07:38 EDT Hillman Solutions acquires Intex DIY - Hillman Solutions announced that it has acquired Intex DIY. This acquisition expands Hillman's Protective Solutions business, which includes America's best-selling work glove, Firm Grip, as well as other consumer favorites like Gorilla Grip, Grease Monkey, AWP and Digz. Additionally, Hillman recently entered into a new partnership with Kontoor Brands to launch work gloves under the popular Wrangler brand, which Hillman expects to roll out in 2025.

07:37 EDT Elevai's Elevai Skincare announces data results from Elevai Enfinity study - Elevai Labs announces the completion of a clinical study examining the effectiveness of Elevai exosomes on facial appearance. The data, pending peer review, from the clinical study was internally reviewed by the Company, and the results show Elevai enfinity to be safe and tolerable with significant improvement noted across many aspects of skin appearance. Elevai aims to publish the full study results in the near future. The study assessed the use of twice-daily Elevai enfinity on 29 study participants over a 12-week period, to determine the efficacy on facial appearance, including measurements like facial firmness, skin tone, wrinkles and smoothness. The study investigated healthy subjects between 40-70 years of age with mild to moderate facial photoaging and sensitive skin.

07:34 EDT BridgeBio announces initiation of scientific collaboration with CarDS Lab - BridgeBio Pharma announced the initiation of a scientific collaboration with the CarDS Lab, led by cardiologist-data scientist, Rohan Khera, M.D., M.S. at Yale School of Medicine, to help address the underdiagnosis of ATTR-CM. The TRACE-AI Network Study will be deployed as a novel paradigm of large-scale federated screening for ATTR-CM that harnesses a central repository of validated AI tools across multiple participating sites to evaluate the scale of ATTR-CM underdiagnosis across the U.S.

07:32 EDT V2X awarded $747M IDIQ contract - V2X announces that it has been awarded a single award indefinite-delivery/indefinite-quantity contract valued at $747M. The F-5 aircraft play a crucial role in training naval pilots by providing adversary combat tactics and simulation capabilities. V2X will be responsible for delivering critical support and operational readiness of the F-5 Adversary aircraft. The work will encompass multiple locations across the United States. Under this firm-fixed price contract, the comprehensive scope of services is projected to continue through November 2028 on the base contract, with three one-year options that could extend through November 2031, bringing the overall contract value to more than $747M.

07:12 EDT Tilray's Breckenridge Brewery announces latest concert series - Breckenridge Brewery announced the next On Tap concert series in partnership with 97.3 KBCO and live music by Kaleo, along with Hippo Campus and Cassandra Lewis. The On Tap concert taking place on Saturday, October 12, 2024, will be an unforgettable night at Breckenridge Brewery's scenic farmhouse in Littleton, Colorado. Proceeds from the event will support Project C.U.R.E., an organization dedicated to providing medical supplies and equipment to those in need across the globe. Founded in Evergreen, Colorado, Project C.U.R.E. has grown to be the largest provider of donated medical resources, with an impressive network of volunteers and minimal overhead costs.

07:10 EDT Sachem Capital appoints Walraven to board of directors - Sachem Capital announced that its Board of Directors has appointed Jeffery Walraven to the Board, effective August 21, 2024. Walraven will also stand for election at the Company's 2024 Annual Meeting of Shareholders. Walraven is Co-Founder and Chief Operating Officer of Freehold Properties.

07:09 EDT Eliem Therapeutics appoints Kaplan as COO, Rampal as SVP, Clinical Development - Eliem Therapeutics announced the appointments of Brett Kaplan, M.D., as Chief Operating Officer, COO, and Nishi Rampal, M.D., as Senior Vice President, SVP, Clinical Development. Before joining Eliem, Dr. Kaplan served as President, Chief Financial and Corporate Development Officer at Chroma Medicine. Prior to Eliem, Dr. Rampal was the Executive Director Clinical Development at Horizon Therapeutics.

07:08 EDT Ocugen announces Health Canada sent "No Objection Letter" for OCU400 trial - Ocugen announced that Health Canada provided a "No Objection Letter" to initiate the OCU400 Phase 3 liMeliGhT clinical trial in Canada. OCU400 is a modifier gene therapy product candidate being developed for retinitis pigmentosa. "Expanding the clinical trial to Canada is significant as it will provide an opportunity to reach a broader patient population encompassing many gene mutations associated with RP," said Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen. "The Health Canada trial will run in parallel with the U.S. FDA trial, expediting the ability to potentially provide a gene-agnostic treatment option to approximately 110,000 patients in the United States and Canada."

07:06 EDT Regeneron announces EC approved Ordspono for adults - Regeneron Pharmaceuticals announced that the European Commission, EC, has approved Ordspono to treat adult patients with relapsed or refractory follicular lymphoma or R/R diffuse large B-cell lymphoma, DLBCL, after two or more lines of systemic therapy. This marks the first regulatory approval of Ordspono in the world for these patients. Ordspono is a bispecific antibody that acts by linking the lymphoma cell to a killer T cell. The approval is based on results from the Phase 1 ELM-1 and pivotal Phase 2 ELM-2 trials, which demonstrated robust, durable response rates in adults with R/R FL or R/R DLBCL: In R/R FL, results from ELM-2 as assessed by an independent review committee showed an objective response rate of 80%, with 73% achieving a complete response. Among complete responders, the median duration of response was 25 months. In R/R DLBCL, results from ELM-2 in patients who were CAR-T therapy naive, as assessed by an IRC showed 52% ORR, with 31% achieving a CR. Among complete responders the median DoR was 18 months. results from ELM-1 in patients who had progressed after CAR-T therapy, as assessed by an IRC showed 48% ORR, with 32% achieving a CR. Among responders, the median DoR was 15 months. The most common adverse reactions were cytokine release syndrome, neutropenia, pyrexia, anemia, thrombocytopenia, diarrhea and COVID-19. The most common serious adverse reactions were CRS, pneumonia, COVID-19 and pyrexia. Ordspono can cause serious or fatal infections, and CRS, which may be serious or life-threatening.

07:04 EDT Gogo announces partnership with Skyservice Business Aviation - Gogo Business Aviation announced a partnership with Skyservice Business Aviation, a North American leader in business aviation, to develop Supplemental Type Certificates from Transport Canada Civil Aviation and the Federal Aviation Administration for Gogo 5G on six aircraft models. Gogo 5G will provide North American operators with enhanced air-to-ground inflight entertainment and connectivity, bolstered by a network of more than 159 sites, 9 of which are located in Canada, as Gogo continues to expand its 5G Canadian coverage.

07:04 EDT Abaxx Technologies files early warning report with respect to MineHub - Abaxx Technologies has filed an early warning report in respect of MineHub Technologies. On August 23, 2024, pursuant to a share exchange agreement between Abaxx and MineHub dated July 31, 2024, Abaxx completed a first tranche closing and acquired 4,166,677 common shares of MineHub and 8,333,333 common share purchase warrants of MineHub. Each Warrant entitles Abaxx to acquire one common share of MineHub at a price of $0.35 per Warrant Share until November 15, 2024. Immediately prior to the First Tranche Closing, Abaxx did not hold any MineHub Shares. Immediately after the First Tranche Closing, Abaxx acquired 4,166,667 Minehub Shares and 8,333,333 Warrants, representing 5.76% of the issued and outstanding MineHub Shares on an undiluted basis and 15.5% of the MineHub Shares on a partially diluted basis. The MineHub shares held by Abaxx are for investment purposes.

07:02 EDT Repligen to present at Wells Fargo Conferences - Repligen Corporation announced that it will be presenting at the Wells Fargo Healthcare Conference being held September 4-6 in Boston. Olivier Loeillot, President and Chief Executive Officer will participate in an analyst-led discussion on Friday, September 6.

07:02 EDT Tonix Pharmaceuticals, Bilthoven announce collaboration to advance TNX-801 - Tonix Pharmaceuticals and Bilthoven Biologicals announced a collaboration to advance TNX-801, Tonix's mpox vaccine candidate. TNX-801 is a live replicating, attenuated virus vaccine based on horsepox in preclinical development to prevent mpox and smallpox. "The recent mpox outbreak exemplifies precisely why we built the pandemic preparedness facility at BBio," said Jurgen Kwik, Chief Executive Officer of Bilthoven Biologicals. "The establishment of the 'ever-warm' facility for pandemic preparedness underscores the critical importance of readiness in the face of global health emergencies, such as mpox. This collaboration encapsulates the essential role of the facility in bolstering pandemic preparedness and response capabilities."

06:48 EDT Granite Point Mortgage CFO Marcin Urbaszek to step down, Blake Johnson succeeds - Granite Point Mortgage Trust announced that Blake Johnson will be appointed CFO, effective December 1, 2024. Johnson will join the company no later than October 28, 2024, as Deputy CFO before assuming the CFO role. This appointment follows Marcin Urbaszek, the company's current CFO, submitting a letter of resignation to the company's Board of Directors notifying it of his intention to step down from his position to pursue a professional opportunity with a global financial institution. Urbaszek will remain with Granite Point until Johnson's official appointment as CFO in December to facilitate a smooth transition.

06:37 EDT Uber fined EUR 290M by Dutch Data Protection Authority - The Dutch Data Protection Authority imposed a fine of EUR 290M on Uber. The agency found that Uber transferred personal data of European taxi drivers to the United States and "failed to appropriately safeguard the data with regard to these transfers." According to the Dutch DPA, "this constitutes a serious violation of the General Data Protection Regulation." The agency says Uber has ended the violation. Reference Link

06:05 EDT DexCom announces Stelo now available without a prescription - DexCom announced that Stelo, the first over-the-counter glucose biosensor in the U.S., is now available for purchase without a prescription at Stelo.com.

06:01 EDT BeiGene announces FDA grants Fast Track Designation to BGB-16673 - BeiGene announced that the U.S. FDA has granted Fast Track Designation to BGB-16673, an orally available investigational Bruton's tyrosine kinase targeting chimeric degradation activation compound, for adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have been previously treated with at least two prior lines of therapy, including BTK inhibitor and B-cell lymphoma 2 inhibitor.

05:11 EDT Regeneron announces latest Dupixent, itepekimab data at ERS - Regeneron (REGN) announced 20 abstracts across Dupixent and investigational therapy itepekimab will be presented at the European Respiratory Society, or ERS, Congress 2024 being held from September 7 to 11 in Vienna, Austria. These clinical and real-world abstracts presented in collaboration with Sanofi (SNY) include four oral presentations and demonstrate the potential of targeting key drivers of type 2 inflammation and other pathways to address respiratory diseases, such as COPD and asthma, and improve patient outcomes. Among the notable Dupixent presentations at ERS is a pooled analysis of the previously reported Phase 3 BOREAS and NOTUS trials in uncontrolled COPD with evidence of type 2 inflammation. In the trials, all patients were on background maximal standard-of-care inhaled therapy. BOREAS and NOTUS formed the basis of the recent European Commission approval and regulatory submissions around the world for Dupixent in certain patients with uncontrolled COPD. As shared in the abstract, the pooled analysis demonstrated that Dupixent patients experienced a 31% reduction in the annualized rate of moderate or severe COPD exacerbations over 52 weeks compared to placebo. Additional COPD data to be presented at the meeting will evaluate the impact of Dupixent on daily symptom frequency and severity, exacerbations and lung function regardless of baseline body mass index, airflow obstruction, dyspnea and exercise capacity measures. Safety results were generally consistent with the known safety profile of Dupixent in its approved indications. Adverse events more commonly observed with Dupixent compared to placebo in either COPD trial were back pain, COVID-19, diarrhea, headache and nasopharyngitis. Additionally, new research will be shared from the Phase 4 VESTIGE trial, a novel imaging study evaluating the effects of Dupixent on airway remodeling in certain adults with asthma. Two poster presentations will show new data on the 4-week impact of Dupixent treatment on airway inflammation, volume, and flow, and mucus plugging, as well as outcomes for clinical remission after 4 and 24 weeks of treatment in adults with uncontrolled moderate-to-severe asthma.